Business Context and Reporting Period
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics targeting the transforming growth factor-beta (TGF-β) family of proteins. The company's lead product candidate, elritercept (KER-050), is in Phase 2 trials for myelodysplastic syndromes (MDS) and myelofibrosis. Other candidates include cibotercept (KER-012) for pulmonary arterial hypertension and KER-065 for obesity and neuromuscular diseases. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $0.4 million | $0.01 million | $0.5 million | $0.01 million |
| Net Loss | $(53.0) million | $(39.4) million | $(141.3) million | $(112.7) million |
| Net Loss Per Share | $(1.41) | $(1.33) | $(3.88) | $(3.86) |
| Operating Expenses | $(59.0) million | $(43.3) million | $(158.1) million | $(123.5) million |
| Cash and Cash Equivalents (End of Period) | $530.7 million | $287.9 million | N/A | |
| Accumulated Deficit | $(522.8) million | $(341.2) million | N/A |
Liquidity and Debt: The company reported no debt outstanding as of September 30, 2024. Cash and cash equivalents increased significantly to $530.7 million, driven by financing activities. Management believes existing cash resources are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Increase: Revenue rose to $0.4 million in Q3 2024 from $0.01 million in Q3 2023. This increase is attributed to service revenue from the clinical product supply agreement with Hansoh (Shanghai) Healthtech Co., Ltd.
- Expense Growth: Total operating expenses increased by $15.8 million in Q3 2024 compared to the prior year quarter. Research and Development (R&D) expenses rose by $15.1 million, driven by increased clinical spend for elritercept (Phase 2 and planned Phase 3), cibotercept (Phase 2), and KER-065 (Phase 1), as well as increased personnel costs.
- Financing Activity: The company raised approximately $306.5 million in net proceeds during the nine months ended September 30, 2024. This included $151.1 million from a January 2024 underwritten public offering and $155.5 million from At-The-Market (ATM) offerings.
- Dividend Income: Other income, net, increased to $5.7 million in Q3 2024 from $3.8 million in Q3 2023, primarily due to higher dividend income from money market funds.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Elritercept: The company expects to report additional data from Part 2 of the Phase 2 trial in lower-risk MDS in Q4 2024. It also expects to announce additional data from the RESTORE trial (myelofibrosis) in Q4 2024. Management anticipates providing details on the planned pivotal Phase 3 trial design in Q4 2024.
- Cibotercept: Enrollment for the Phase 2 TROPOS trial in pulmonary arterial hypertension was completed in September 2024. Topline data is expected in Q2 2025.
- KER-065: Initial data from the Phase 1 trial in healthy volunteers is expected in Q1 2025.
Risks and Contingencies:
- Capital Requirements: The company has incurred net losses since inception and expects to continue doing so. It will require substantial additional funding to complete development and commercialization. Failure to secure capital could force delays or reductions in operations.
- Clinical Uncertainty: All product candidates are in clinical development. There is no guarantee of success in clinical trials, regulatory approval, or commercialization.
- Third-Party Reliance: The company relies on third parties for manufacturing and clinical trial conduct. Disruptions with these partners could delay development.
- Intellectual Property: Success depends on protecting IP rights, which involves significant cost and uncertainty.
Investor Verification Checklist
- Cash Runway: Verify the company's burn rate against the $530.7 million cash balance to confirm the ability to fund operations through the planned Phase 3 trial of elritercept.
- Elritercept Phase 3 Design: Monitor the Q4 2024 announcement regarding the Phase 3 trial design and FDA alignment for lower-risk MDS.
- ATM Offering Capacity: Note that approximately $191.9 million remains available under the current ATM agreement; track future sales for potential dilution.
- Hansoh Collaboration: Review the status of the technology transfer and supply agreements with Hansoh, as this is the current source of revenue.
- Stock-Based Compensation: Assess the impact of the $25.7 million in stock-based compensation expense (9 months 2024) on future cash flow and dilution.